Adverse urinary effects of allopurinol in dogs with leishmaniasis

M. Torres; J. Pastor; X. Roura; M. D. Tabar; Y. Espada; A. Font; J. Balasch; M. Planellas

doi:10.1111/jsap.12484

Adverse urinary effects of allopurinol in dogs with leishmaniasis

M. Torres, J. Pastor, X. Roura, M. D. Tabar, Y. Espada, A. Font, J. Balasch, M. Planellas

Research output: Contribution to journal › Article › Research › peer-review

28 Citations (Scopus)

Abstract

© 2016 British Small Animal Veterinary Association. OBJECTIVE: The objective of this study was to describe the adverse effects of allopurinol on the urinary system during treatment of canine leishmaniasis. METHODS: Retrospective case series of 42 dogs that developed xanthinuria while receiving allopurinol treatment for leishmaniasis. RESULTS: Of 320 dogs diagnosed with leishmaniasis, 42 (13%) developed adverse urinary effects. Thirteen (of 42) dogs (31%) developed xanthinuria, renal mineralisation and urolithiasis; 11 (26·2%) showed xanthinuria with renal mineralisation; 9 (21·4%) had xanthinuria with urolithiasis and 9 (21·4%) developed xanthinuria alone. Urinary clinical signs developed in 19 dogs (45·2%). CLINICAL SIGNIFICANCE: This study demonstrates that urolithiasis and renal mineralisation can occur in dogs receiving allopurinol therapy. Dogs receiving therapy should be monitored for the development of urinary adverse effects from the beginning of treatment.

Original language	English
Pages (from-to)	299-304
Journal	Journal of Small Animal Practice
Volume	57
Issue number	6
DOIs	https://doi.org/10.1111/jsap.12484
Publication status	Published - 1 Jun 2016

Access to Document

10.1111/jsap.12484

Cite this

@article{bcee9db65695490a9d375b6d3ae3ccda,

title = "Adverse urinary effects of allopurinol in dogs with leishmaniasis",

abstract = "{\textcopyright} 2016 British Small Animal Veterinary Association. OBJECTIVE: The objective of this study was to describe the adverse effects of allopurinol on the urinary system during treatment of canine leishmaniasis. METHODS: Retrospective case series of 42 dogs that developed xanthinuria while receiving allopurinol treatment for leishmaniasis. RESULTS: Of 320 dogs diagnosed with leishmaniasis, 42 (13%) developed adverse urinary effects. Thirteen (of 42) dogs (31%) developed xanthinuria, renal mineralisation and urolithiasis; 11 (26·2%) showed xanthinuria with renal mineralisation; 9 (21·4%) had xanthinuria with urolithiasis and 9 (21·4%) developed xanthinuria alone. Urinary clinical signs developed in 19 dogs (45·2%). CLINICAL SIGNIFICANCE: This study demonstrates that urolithiasis and renal mineralisation can occur in dogs receiving allopurinol therapy. Dogs receiving therapy should be monitored for the development of urinary adverse effects from the beginning of treatment.",

author = "M. Torres and J. Pastor and X. Roura and Tabar, {M. D.} and Y. Espada and A. Font and J. Balasch and M. Planellas",

year = "2016",

month = jun,

day = "1",

doi = "10.1111/jsap.12484",

language = "English",

volume = "57",

pages = "299--304",

journal = "Journal of Small Animal Practice",

issn = "0022-4510",

number = "6",

}

TY - JOUR

T1 - Adverse urinary effects of allopurinol in dogs with leishmaniasis

AU - Torres, M.

AU - Pastor, J.

AU - Roura, X.

AU - Tabar, M. D.

AU - Espada, Y.

AU - Font, A.

AU - Balasch, J.

AU - Planellas, M.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - © 2016 British Small Animal Veterinary Association. OBJECTIVE: The objective of this study was to describe the adverse effects of allopurinol on the urinary system during treatment of canine leishmaniasis. METHODS: Retrospective case series of 42 dogs that developed xanthinuria while receiving allopurinol treatment for leishmaniasis. RESULTS: Of 320 dogs diagnosed with leishmaniasis, 42 (13%) developed adverse urinary effects. Thirteen (of 42) dogs (31%) developed xanthinuria, renal mineralisation and urolithiasis; 11 (26·2%) showed xanthinuria with renal mineralisation; 9 (21·4%) had xanthinuria with urolithiasis and 9 (21·4%) developed xanthinuria alone. Urinary clinical signs developed in 19 dogs (45·2%). CLINICAL SIGNIFICANCE: This study demonstrates that urolithiasis and renal mineralisation can occur in dogs receiving allopurinol therapy. Dogs receiving therapy should be monitored for the development of urinary adverse effects from the beginning of treatment.

AB - © 2016 British Small Animal Veterinary Association. OBJECTIVE: The objective of this study was to describe the adverse effects of allopurinol on the urinary system during treatment of canine leishmaniasis. METHODS: Retrospective case series of 42 dogs that developed xanthinuria while receiving allopurinol treatment for leishmaniasis. RESULTS: Of 320 dogs diagnosed with leishmaniasis, 42 (13%) developed adverse urinary effects. Thirteen (of 42) dogs (31%) developed xanthinuria, renal mineralisation and urolithiasis; 11 (26·2%) showed xanthinuria with renal mineralisation; 9 (21·4%) had xanthinuria with urolithiasis and 9 (21·4%) developed xanthinuria alone. Urinary clinical signs developed in 19 dogs (45·2%). CLINICAL SIGNIFICANCE: This study demonstrates that urolithiasis and renal mineralisation can occur in dogs receiving allopurinol therapy. Dogs receiving therapy should be monitored for the development of urinary adverse effects from the beginning of treatment.

U2 - 10.1111/jsap.12484

DO - 10.1111/jsap.12484

M3 - Article

SN - 0022-4510

VL - 57

SP - 299

EP - 304

JO - Journal of Small Animal Practice

JF - Journal of Small Animal Practice

IS - 6

ER -

Adverse urinary effects of allopurinol in dogs with leishmaniasis

Abstract

Access to Document

Fingerprint

Cite this